{{Drugbox
| Watchedfields = changed
| verifiedrevid = 447550624
| IUPAC_name = 11-chloro-2,8-dimethyl-12b-phenyl-6''H''-[1,3]oxazino[3,2-d][1,4]benzodiazepine-4,7-dione<ref>{{cite journal | journal = Acta Crystallogr C |date=July 2001 | volume = 57 | issue = Pt 7 | pages = 848–50 | title = Ketazolam | author = Vega D |author2=Fernández D |author3=Echeverría G  | pmid = 11443263 | doi = 10.1107/S0108270101006175}}</ref>
| image = Ketazolam.svg
| width = 175
| image2 = Ketazolam3d.png
| width2 = 150

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|CONS|ketazolam}}
| pregnancy_category =
| legal_CA = Schedule IV
| legal_DE = Rx-only/Anlage III
| legal_US = Schedule IV
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =
| metabolism = [[Liver|Hepatic]]
| elimination_half-life = 26–200 hours
| excretion = [[Kidney|Renal]]

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 27223-35-4
| ATC_prefix = N05
| ATC_suffix = BA10
| PubChem = 33746
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01587
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 31110
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 92A214MD7Y
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04650

<!--Chemical data-->
| C=20 | H=17 | Cl=1 | N=2 | O=3
| molecular_weight = 368.8
| smiles = ClC1=CC2=C(N(C)C(CN3C(C=C(C)OC32C4=CC=CC=C4)=O)=O)C=C1
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C20H17ClN2O3/c1-13-10-18(24)23-12-19(25)22(2)17-9-8-15(21)11-16(17)20(23,26-13)14-6-4-3-5-7-14/h3-11H,12H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = PWAJCNITSBZRBL-UHFFFAOYSA-N
}}

'''Ketazolam''' (marketed under the brand names '''Anseren''', '''Ansieten''', '''Ansietil''', '''Marcen''', '''Sedatival''', '''Sedotime''', '''Solatran''' and '''Unakalm''') is a drug which is a [[benzodiazepine]] derivative. It possesses [[anxiolytic]], [[anticonvulsant]], [[sedative]] and [[skeletal muscle relaxant]] properties.

==Therapeutic uses==
It is used for the treatment of anxiety and has similar effectiveness compared to diazepam. Ketazolam also appears to produce a reduced level of side effects such as sedation compared with [[diazepam]] and the side effects when they occur tend to be milder.<ref>{{cite journal | journal = The Journal of Clinical Psychiatry|date=November 1980 | volume =41 | issue =11 | pages =386–92 | title =Double-blind comparison of ketazolam, diazepam and placebo in once-a-day vs t.i.d. dosing | author =Anhalt HS |author2=Young R |author3=Roginsky M  | pmid =6108319 }}</ref><ref>{{cite journal | journal =Clin Ther | year =1980 | volume =3 | issue =1 | pages =9–14 | title =Anxiolytic efficacy and safety of ketazolam compared with diazepam and placebo | author =Kim KK |author2=Sirman A |author3=Trainor FS |author4=Lee BY  | pmid =6105920 }}</ref><ref>{{cite journal | journal =J Int Med Res | year =1976 | volume =4 | issue =1 | pages =50–4 | title =Double-blind placebo-controlled efficacy study of ketazolam (U-28,774) | author =Fabre LF Jr |author2=Harris RT  | pmid =16791 }}</ref><ref>{{cite journal | journal =J Clin Pharmacol |date=October 1980 | volume =20 | issue =10 | pages =581–9 | title =Ketazolam and diazepam in anxiety: a controlled study | author =Rickels K |author2=Csanalosi I |author3=Greisman P |author4=Mirman MJ |author5=Morris RJ |author6=Weise CC |author7=Weiss G  | pmid =6108335 | doi=10.1002/j.1552-4604.1980.tb01673.x}}</ref> Ketazolam is also an effective antispasmodic drug and is used for the treatment of spasticity.<ref>{{cite journal | journal =Arch Phys Med Rehabil |date=August 1986 | volume =67 | issue =8 | pages =556–7 | title =Ketazolam once daily for spasticity: double-blind cross-over study | author =Basmajian JV |author2=Shankardass K |author3=Russell D  | pmid =2874780 }}</ref><ref>{{cite journal | journal =Am J Phys Med Rehabil |date=June 1988 | volume =67 | issue =3 | pages =108–16 | title =Management of spasticity | author =Katz RT | pmid =3288246 | doi =10.1097/00002060-198806000-00004 }}</ref><ref>{{cite journal | journal =Arch Phys Med Rehabil |date=November 1984 | volume =65 | issue =11 | pages =698–701 | title =Ketazolam treatment for spasticity: double-blind study of a new drug | author =Basmajian JV |author2=Shankardass K |author3=Russell D |author4=Yucel V  | pmid =6149738 }}</ref>

==Availability==
Ketazolam is not approved for sale in [[Australia]], [[United Kingdom]] or the [[United States]].<ref>{{cite web|url=http://www.non-benzodiazepines.org.uk/benzodiazepine-names.html#Ketazolam |title=Benzodiazepine Names |accessdate=26 August 2008 |publisher=The Tranquilliser Recovery and Awareness Place |deadurl=yes |archiveurl=https://web.archive.org/web/20081208054743/http://www.non-benzodiazepines.org.uk/benzodiazepine-names.html |archivedate= 8 December 2008 |df= }}</ref> In [[South Africa]], [[GlaxoSmithKline]] markets ketazolam under its Solatran brand name.<ref>{{cite web|url=http://home.intekom.com/pharm/smith_kb/solatran.html|title=SOLATRAN 15 (capsules) - SOLATRAN 30 (capsules)|accessdate=26 August 2008|date=12 November 1985|publisher=South African Electronic Package Inserts}}</ref>  In Canada, ketazolam is listed in schedule IV of the Controlled Drugs and Substances Act, along with other benzodiazepines.<ref>http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-26.html#h-29 {{webarchive|url=https://web.archive.org/web/20131215170432/http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-26.html |date=2013-12-15 }}</ref>

==Tolerance and physical dependence==
Chronic use of ketazolam as with other [[benzodiazepines]] can lead to [[physical dependence]] and the appearance of the [[benzodiazepine withdrawal syndrome]] upon cessation of use or decrease in dose. [[drug tolerance|Tolerance]] to ketazolam's therapeutic effects occurs over a period of 15 days.<ref>{{cite journal | journal =Psychol Med Monogr Suppl | year =1988 | volume =13 | pages =1–55 | title =The natural history of tolerance to the benzodiazepines | author =Higgitt A |author2=Fonagy P |author3=Lader M  | pmid =2908516 | doi =10.1017/S0264180100000412 }}</ref>

==Contraindications and special caution==
Benzodiazepines require special precaution if used in the elderly, during pregnancy, in children, alcohol or drug-dependent individuals and individuals with [[comorbid]] [[psychiatric disorders]].<ref>{{Cite journal | last1 = Authier | first1 = N. | last2 = Balayssac | first2 = D. | last3 = Sautereau | first3 = M. | last4 = Zangarelli | first4 = A. | last5 = Courty | first5 = P. | last6 = Somogyi | first6 = AA. | last7 = Vennat | first7 = B. | last8 = Llorca | first8 = PM. | last9 = Eschalier | first9 = A. <!--exactly 9 authors--> | title = Benzodiazepine dependence: focus on withdrawal syndrome. | journal = Ann Pharm Fr | volume = 67 | issue = 6 | pages = 408–13 |date=Nov 2009 | doi = 10.1016/j.pharma.2009.07.001 | pmid = 19900604 }}</ref>

==Pharmacokinetics==
Ketazolam breaks down in the blood to [[diazepam]] which breaks down to [[demoxepam]] which breaks down to [[desmethyldiazepam]].<ref>{{cite journal | journal = Biomed Mass Spectrom. |date=June 1984| volume = 11| issue = 6| pages = 284–9| title = The decomposition of benzodiazepines during analysis by capillary gas chromatography/mass spectrometry|vauthors=Joyce JR, Bal TS, Ardrey RE, Stevens HM, Moffat AC | pmid = 6743768| doi = 10.1002/bms.1200110607}}</ref>

==Warnings==
The U.S. [[Food and Drug Administration]] warns that in Spain, ketazolam marketed as Marcen may sometimes be mistakenly confused with Narcan.<ref>{{cite web
 |url=http://www.fda.gov/oc/opacom/reports/confusingnames.html 
 |title=FDA Public Health Advisory - Consumers Filling U.S. Prescriptions Abroad May Get the Wrong Active Ingredient Because of Confusing Drug Names 
 |accessdate=26 August 2006 
 |author=Food and Drug Administration 
 |authorlink=Food and Drug Administration 
 |date=January 2006 
 |publisher=FDA (USA) 
 |archiveurl=https://web.archive.org/web/20060812000720/http://www.fda.gov/oc/opacom/reports/confusingnames.html 
 |archivedate=12 August 2006 
 |deadurl=yes 
 |df= 
}}</ref>

==Legal status==
Ketazolam is a List 3 drug under the [[Betäubungsmittelgesetz]], like almost all benzodiazepines in Germany. Ketazolam is a List II drugs of the [[Opium Law]] in the [[Netherlands]]. Ketazolam is a [[Controlled Substances Act#Schedule IV controlled substances|Schedule IV]] drug under the Controlled Substances Act in the US.<ref>{{cite web|url= http://www.dea.gov/pubs/scheduling.html|title= Drug Scheduling|accessdate= 26 August 2008|author= Drug Enforcement Administration (USA)|authorlink=Drug Enforcement Administration|publisher= United States Government}}</ref>

==References==
{{Reflist|2}}

{{Benzodiazepines}}
{{Anxiolytics}}
{{GABAAR PAMs}}

[[Category:Benzodiazepines]]
[[Category:Chloroarenes]]
[[Category:GABAA receptor positive allosteric modulators]]
[[Category:Lactams]]